Back to results
US 11,958,904 B2Granted
Engineered antibody Fc variants for enhanced serum half life
AssigneeResearch Development Foundation
InventorsGeorge Georgiou, Chang-Han Lee, Tae Hyun Kang
Life of this patent
Estimating the term…
Abstract
In some aspects, mutant or variant Fc domains are provided that exhibit increased binding to FcRn and increased half-life after administration in vivo. The Fc domain may be comprised in a glycosylated or aglycosylated antibody. Methods for using the mutant or variant Fc domains or polypeptides comprising the mutant or variant Fc domains are also provided.
Claims41
A nucleic acid encoding a polypeptide comprising a variant IgG Fc domain that binds human FcRn at an acidic pH, wherein the Fc domain has the following substitutions:
- (i) aspartic acid at position 309 (L/V309D);
- (ii) histidine at position 311 (Q311H);
- and (iii) a substitution at position 434 of either a serine or tyrosine (N434Y or N434S);
- with amino acid position numbering being according to the Kabat system.
1 more element
Dependencies are inferred from the claim text.